Psilocybin for depression and anxiety associated with life-threatening illnesses
(Source: Journal of Psychopharmacology)
Source: Journal of Psychopharmacology - November 29, 2016 Category: Psychiatry Authors: McCorvy, J. D., Olsen, R. H., Roth, B. L. Tags: Commentaries Source Type: research
Psilocybin and palliative end-of-life care
(Source: Journal of Psychopharmacology)
Source: Journal of Psychopharmacology - November 29, 2016 Category: Psychiatry Authors: Shelton, R. C., Hendricks, P. S. Tags: Commentaries Source Type: research
Psycho-existential distress in cancer patients: A return to "entheogens"
(Source: Journal of Psychopharmacology)
Source: Journal of Psychopharmacology - November 29, 2016 Category: Psychiatry Authors: Blinderman, C. D. Tags: Commentaries Source Type: research
Psilocybin in end of life care: Implications for further research
(Source: Journal of Psychopharmacology)
Source: Journal of Psychopharmacology - November 29, 2016 Category: Psychiatry Authors: Summergrad, P. Tags: Commentaries Source Type: research
Psilocybin: Psychotherapy or drug?
(Source: Journal of Psychopharmacology)
Source: Journal of Psychopharmacology - November 29, 2016 Category: Psychiatry Authors: Goodwin, G. M. Tags: Commentaries Source Type: research
Back to the future: Research renewed on the clinical utility of psychedelic drugs
(Source: Journal of Psychopharmacology)
Source: Journal of Psychopharmacology - November 29, 2016 Category: Psychiatry Authors: Lieberman, J. A., Shalev, D. Tags: Commentaries Source Type: research
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that psilocybin may decrease depression and anxiety in cancer patients. The effects of psilocybin were studied in 51 cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety. This randomized, double-blind, cross-over trial investigated the effects of a very low (placebo-like) dose (1 or 3 mg/70 kg) vs. a high dose (22 or 30 mg/70 kg) of psilocybin administered in counterbalanced sequence with 5 weeks between sessions and a 6-month follow-up. Instructions to participants...
Source: Journal of Psychopharmacology - November 29, 2016 Category: Psychiatry Authors: Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., Klinedinst, M. A. Tags: Original Papers Source Type: research
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Conclusions:
In conjunction with psychotherapy, single moderate-dose psilocybin produced rapid, robust and enduring anxiolytic and anti-depressant effects in patients with cancer-related psychological distress.
Trial Registration: ClinicalTrials.gov Identifier: NCT00957359 (Source: Journal of Psychopharmacology)
Source: Journal of Psychopharmacology - November 29, 2016 Category: Psychiatry Authors: Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., Schmidt, B. L. Tags: Original Papers Source Type: research
Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future
(Source: Journal of Psychopharmacology)
Source: Journal of Psychopharmacology - November 29, 2016 Category: Psychiatry Authors: Nutt, D. Tags: Editorial Source Type: research
Oxytocin and emotion processing
Since the observation that oxytocin has key effects on social decision making, research on this exciting neuropeptide has doubled in volume: hundreds of studies have pursued the promise of a specific oxytocin action on high-level cognition and social function with wide potential translational implications (from autism to social anxiety to dementia). Here we review the evidence on whether the complex behavioural effects observed in humans after exogenous oxytocin administration build on changes in basic emotional information processing, in particular emotional facial expressions recognition, and attention and memory for emo...
Source: Journal of Psychopharmacology - November 9, 2016 Category: Psychiatry Authors: Di Simplicio, M., Harmer, C. J. Tags: Commentary Source Type: research
Prediction error, ketamine and psychosis: An updated model
In 2007, we proposed an explanation of delusion formation as aberrant prediction error-driven associative learning. Further, we argued that the NMDA receptor antagonist ketamine provided a good model for this process. Subsequently, we validated the model in patients with psychosis, relating aberrant prediction error signals to delusion severity. During the ensuing period, we have developed these ideas, drawing on the simple principle that brains build a model of the world and refine it by minimising prediction errors, as well as using it to guide perceptual inferences. While previously we focused on the prediction error si...
Source: Journal of Psychopharmacology - November 9, 2016 Category: Psychiatry Authors: Corlett, P. R., Honey, G. D., Fletcher, P. C. Tags: Commentary Source Type: research
Modelling the cognitive and neuropathological features of schizophrenia with phencyclidine
Here, Reynolds and Neill describe the studies that preceded and followed publication of this paper, which reported a deficit in parvalbumin (PV), a calcium-binding protein found in GABA interneurons known to be reduced in schizophrenia patients, in conjunction with a deficit in reversal learning in an animal model for schizophrenia. This publication resulted from common research interests: Reynolds in the neurotransmitter pathology of schizophrenia, and Neill in developing animal models for schizophrenia symptomatology. The animal model, using a sub-chronic dosing regimen (sc) with the non-competitive NMDA receptor antagon...
Source: Journal of Psychopharmacology - November 9, 2016 Category: Psychiatry Authors: Reynolds, G. P., Neill, J. C. Tags: Commentary Source Type: research
Dont panic. A guide to tryptophan depletion with disorder-specific anxiety provocation
The 2002 paper "Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine" by Bell and colleagues – reprinted in this issue of the Journal – reports on a study undertaken in the halcyon days of David Nutt’s Psychopharmacology Unit at the University of Bristol, England. In this invited commentary authors of the original work discuss the impact of this paper on the field of acute tryptophan depletion research (especially in the field of clinical anxiety disorders) and the development of disorder-specific anxiogenic provocations over the past decade. (Source: J...
Source: Journal of Psychopharmacology - November 9, 2016 Category: Psychiatry Authors: Hood, S., Bell, C., Argyropoulos, S., Nutt, D. Tags: Commentary Source Type: research
Looking back (and in)to the future: A personal reflection on 'Serotonin autoreceptor function and antidepressant drug action (Hjorth et al., 2000)
Our article in this journal some 15 years ago focussed on the role of serotonin (5-HT) autoreceptors in the mechanism of action of antidepressant drugs. Specifically in this regard, the results were summarised of rat microdialysis studies carried out to examine: (a) the relative importance of 5-HT1A and 5-HT1B autoreceptors, including (b) possible regional variation, and (c) potential changes in autoreceptor responsiveness following chronic selective serotonin reuptake inhibitor administration. In the present reflection piece, I recap some of the key findings against a brief background and provide an account of their beari...
Source: Journal of Psychopharmacology - November 9, 2016 Category: Psychiatry Authors: Hjorth, S. Tags: Commentary Source Type: research
The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders
The highly-interconnected and neurochemically-rich frontal cortex plays a crucial role in the regulation of mood and cognition, domains disrupted in depression and other central nervous system disorders, and it is an important site of action for their therapeutic control. For improving our understanding of the function and dysfunction of the frontal cortex, and for identifying improved treatments, quantification of extracellular pools of neuromodulators by microdialysis in freely-moving rodents has proven indispensable. This approach has revealed a complex mesh of autoreceptor and heteroceptor interactions amongst monoamin...
Source: Journal of Psychopharmacology - November 9, 2016 Category: Psychiatry Authors: Millan, M. J., Rivet, J.-M., Gobert, A. Tags: Commentary Source Type: research
